Funding for this research was provided by:
National Institutes of Health (R01DC008871, U54HD086984)
Received: 11 January 2019
Accepted: 23 July 2019
First Online: 15 August 2019
Ethics approval and consent to participate
: The study was approved by the CHOP Institutional Review Board, and all participants’ families gave written informed consent. As indicated by institutional policy, where competent to do so, children over the age of seven additionally gave verbal assent, in accordance with the principles of the Declaration of Helsinki.
: Not applicable
: Dr. Roberts declares consulting/advisory board relationships with Prism Clinical Imaging, CTF, Ricoh, Spago Nanomedical and Avexis. Additionally, he and Dr. Edgar disclose intellectual property related to MEG as a biomarker for pharmaceutical therapy, under license to MEGIN. All other authors declare no competing interests.